

Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: A systematic review and meta-analysis

Mary Obasi (✉ mobasi@mednet.ucla.edu)

University Of California, Los Angeles <https://orcid.org/0000-0002-1022-4855>

Arielle Abovich

Johns Hopkins Hospital: Johns Hopkins Medicine

Jacqueline Vo

National Cancer Institute Division of Cancer Epidemiology and Genetics

Yawen Gao

Analysis Group Inc

Stefania Papatheodorou

Harvard University T H Chan School of Public Health

Anju Nohria

DF/HCC: Dana-Farber/Harvard Cancer Center

Aarti Asnani

Beth Israel Deaconess Medical Center CardioVascular Institute

Ann Partridge

Dana-Farber Cancer Institute

Research Article

Keywords: statins, cardiotoxicity, cancer survivors, meta-analysis

Posted Date: May 5th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-485118/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at Cancer Causes & Control on August 18th, 2021. See the published version at <https://doi.org/10.1007/s10552-021-01487-1>.

Abstract

Purpose: Cardiotoxicity affects 5-16% of cancer patients who receive anthracyclines and/or trastuzumab. Limited research has examined interventions to mitigate cardiotoxicity. We examined the role of statins in mitigating cardiotoxicity by performing a systematic review and meta-analysis of published studies.

Methods: A literature search was conducted using PubMed, Embase, Web of Science, ClinicalTrials.gov, and Cochrane Central. A random-effect model was used to assess summary relative risks (RR), weighted mean differences (WMD), and corresponding 95% confidence intervals. Testing for heterogeneity between the studies was performed using Cochran's Q test and the I² test.

Results: Two randomized controlled trials (RCTs) with a total of 117 patients and four observational cohort studies with a total of 813 patients contributed to the analysis. Pooled results indicate significant mitigation of cardiotoxicity after anthracycline and/or trastuzumab exposure among statin users in cohort studies [RR=0.46, 95% CI (0.27-0.78), p=0.004, =0.0%] and a non-significant decrease in cardiotoxicity risk among statin users in RCTs [RR=0.49, 95% CI (0.17-1.45), p=0.20, =5.6%]. Those who used statins were also significantly more likely to maintain left ventricular ejection fraction compared to baseline after anthracycline and/or trastuzumab therapy in both cohort studies [weighted mean difference (WMD)=6.14%, 95% CI (2.75-9.52), p<0.001, =74.7%] and RCTs [WMD=6.25%, 95% CI (0.82-11.68, p=0.024, =80.9%]. We were unable to explore publication bias due to the small number of studies.

Conclusions: This meta-analysis suggests that there is an association between statin use and decreased risk of cardiotoxicity after anthracycline and/or trastuzumab exposure. Larger well-conducted RCTs are needed to determine whether statins decrease risk of cardiotoxicity from anthracyclines and/or trastuzumab.

Trial Registration Number and Date of Registration: PROSPERO: CRD42020140352 on 7/6/2020.

Introduction

Cardiotoxicity is the development of cardiovascular disease or damage to the heart resulting from cancer treatment. Anthracyclines and trastuzumab have demonstrated effectiveness in treating various cancers; however, both are associated with cardiotoxicity, resulting in an asymptomatic decline in left ventricular (LV) ejection fraction or subsequent development of heart failure. The estimated incidence of anthracycline and/or trastuzumab cardiotoxicity ranges from 5-16%, depending on various risk factors [1]. Several studies have examined the risk factors impacting this association among cancer patients [2], [3], yet few have examined prevention or mitigation strategies [4]–[8].

While the mechanisms of cardiotoxicity are not fully understood, it is hypothesized that anthracyclines cause oxidative damage to cardiac tissues resulting in cardiac cell death, which can ultimately lead to heart failure. If detected late, this cardiac damage can be irreversible [9]. Trastuzumab is primarily given to women with HER2-overexpressing breast cancer to block HER2 signaling, and in doing so it suppresses autophagy in cardiomyocytes to trigger accumulation of toxic reactive oxygen species (ROS) within cardiomyocytes [10]. Trastuzumab-induced LV dysfunction can often be reversible with discontinuation of therapy, and many patients can tolerate re-challenge after institution of neurohormonal antagonists for heart failure [10]. Often, anthracyclines and trastuzumab may be given sequentially, resulting in a significantly higher risk of cardiotoxicity [11].

Statins, also known as hydroxymethyl glutaryl coenzyme A reductase (HMG-CoA) inhibitors, are clinically well established for cardiovascular disease prevention due to their anti-inflammatory, anti-oxidative, and cholesterol-lowering effects [12]. Beyond these properties, statins have pleiotropic effects via inhibition of small Ras homologous (Rho) GTPases. These effects reduce topoisomerase II inhibition and the generation of reactive oxygen species, both mechanisms implicated in the pathophysiology of anthracycline and/or trastuzumab induced cardiotoxicity. Therefore, statins may mitigate the risk of cardiotoxicity among cancer patients receiving these therapies [13].

The aim of this meta-analysis is to summarize the literature on statins as a mitigation modality for cardiotoxicity among cancer survivors treated with anthracyclines and/or trastuzumab and compile evidence on their effectiveness. The research question is: Does statin use lower the risk of cardiotoxicity among cancer survivors treated with anthracyclines and/or trastuzumab?

Methods

This systematic review and meta-analysis were performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [14], [15]. Ethical approval was not necessary because this study was a meta-analysis. The meta-analysis protocol was registered on PROSPERO: CRD42020140352 on July 7, 2020.

Literature Search Strategy

A literature search was conducted in the databases Pubmed, Embase, Web of Science, ClinicalTrials.gov, and Cochrane Central using predefined keywords to identify articles examining statin use as a preventive method for the development of cardiotoxicity among cancer patients treated with anthracyclines and/or trastuzumab. See Supplementary Table 1 for the search criteria for each database. We used both medical subject headings

and text words in PubMed, and we used Emtree terms and text words in Embase. We used text words in Web of Science, and ClinicalTrials.gov. Additionally, reference lists were reviewed for additional studies.

Selection Criteria

Two reviewers independently selected eligible studies (M. Obasi, A. Abovich). Disagreements between selected studies were settled after discussing with a third reviewer (J. Vo). The inclusion criteria consisted of studies which included cancer patients treated with anthracyclines and/or trastuzumab, and where statins were used during cancer treatment. The exclusion criteria consisted of case reports, reviews, guidelines, editorials, letters, and non-human research.

Data Extraction

Titles and/or abstracts were screened independently by two reviewers (M. Obasi, A. Abovich), based on the inclusion and exclusion criteria. The full texts of potentially eligible articles were screened independently by the same two authors for eligibility. The following information was obtained for this study-level meta-analysis: sample size, country of origin, details of the intervention and control conditions, study methodology, study settings, and outcomes. The reviewers (M. Obasi, A. Abovich) extracted and screened articles independently. Discrepancies were discussed to reach consensus.

Variables

We identified studies that included patients taking any of the following statins: fluvastatin, atorvastatin, lovastatin, pravastatin, pitavastatin, rosuvastatin, and simvastatin. Study populations included patients who were diagnosed with any type of cancer and treated with either anthracyclines, trastuzumab, or both.

The primary outcome was the development of cardiotoxicity, defined as 1) incident heart failure diagnoses or 2) cardiotoxicity defined as reduction in LV ejection fraction of >10% to <55% without symptoms of heart failure, or >5% drop to <55% with symptoms, or reduction in LV ejection fraction to <50%, by the Cardiac Review and Evaluation Committee [16]. The secondary outcome was mean change in LV ejection fraction from the pretreatment (baseline) value to follow-up.

Methodological Quality Assessment

We assessed the quality of randomized controlled trials (RCTs) using version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2). The following domains were critiqued: (1) bias arising from the randomization process, (2) bias due to deviations from intended interventions, (3) bias due to missing outcome data, (4) bias in measurement of the outcome, and (5) bias in selection of the reported result. Each was graded "low risk of bias (+)", "high risk of bias (x)", or "some concerns (-)".

The Newcastle–Ottawa Scale has eight items that are categorized into three perspectives: selection of study groups (four items, one star each), comparability of the groups (one item, up to two stars), and ascertainment of the outcome (three items, one star each). A "star" represents a "high-quality" choice of individual study. Two reviewers independently selected eligible studies (M. Obasi, A. Abovich). Disagreements about selected studies were settled after further discussion.

Data Synthesis and Analysis

We conducted two separate analyses examining the primary and secondary outcomes. First, we analyzed pooled relative risks using study-specific estimates for incidence of cardiotoxicity. Inverse variance weighting was used for the random effects model.

For the secondary outcome, we examined the weighted mean difference (WMD) for change in LV ejection fraction using the random-effects model with inverse variance weighting. The WMD for LV ejection fraction was the difference in ejection fractions from baseline to follow-up compared between groups. Statistical significance was set at $\alpha = .05$. All analyses were conducted with Stata version 15.

Testing for heterogeneity between the studies was performed using Cochran's Q test [17] and the I^2 test [18]. A p-value of <0.05 or an I^2 higher than 50% were considered significant evidence of heterogeneity. Publication bias was not assessed due to the small number of studies.

Results

Search Results and Characteristics of Included Studies

The initial database search yielded a total of 3,603 records, as shown in the PRISMA flow diagram (Figure 1). There were 1,068 duplicates removed. After screening the titles and abstracts of the remaining studies (M. Obasi, A. Abovich), 28 records were identified. After more detailed evaluation, 22 records were excluded for details listed in Figure 1. A total of six studies were included in the meta-analysis, including four observational cohort studies with a total of 813 patients [19]–[22] and two RCTs with a total of 117 patients [23], [24].

Table 1 describes the study characteristics. The age of participants in the RCTs ranged from 35 to 69 years. One RCT randomized newly diagnosed breast cancer patients to daily rosuvastatin or placebo starting the day before treatment with anthracycline and/or trastuzumab [23]. The other RCT randomized patients with various hematologic malignancies to daily atorvastatin or no statin prior to the initiation of anthracycline based therapy [24]. Both RCTs followed patients through 6 months of cancer treatment. Fifty percent (58/117) of patients in the two RCTs were randomized to statin therapy.

The age of participants in the observational cohort studies ranged from 40 to 70 years. These studies included patients with breast cancer, gastric cancer, leukemia, and lymphoma who had received treatment with anthracyclines and/or trastuzumab. Study duration ranged from 6 months to over 4 years. One-third (268/813) of participants in the cohort studies were exposed to statins during cancer therapy. One study specifically excluded patients with prior heart failure [22]. In all cohort studies, patients receiving statins had a higher prevalence of cardiovascular risk factors or established coronary artery disease [20, 22, 23]

The primary outcome, cardiotoxicity, was examined in three cohort studies [19], [20], [22] and two RCTs [23], [24]. Two cohort studies [19], [21] and two RCTs [23], [24] also examined the secondary outcome, mean change in LV ejection fraction. LV ejection fraction was measured by either echocardiography, multigated acquisition (MUGA) scan, or cardiovascular magnetic resonance imaging (cMRI) (Table 2).

Quality Assessment Results

Figure 2 shows our judgements from evaluating the five domains of the Cochrane risk-of-bias tool for the two RCTs. Most domains were at “low risk.” There was some concern about lack of blinding of participants and personnel in Acar et al. [24]. Table 3 summarizes the quality of the cohort studies based on Newcastle–Ottawa Scale scores. The scores ranged from 3 to 8, with a median of 7. Three studies were of high quality (≥ 6). The medians for each of the three perspectives were 2 for selection of study groups, 2 for comparability of the groups, and 3 for ascertainment of the outcome. Lower quality scores arose from the omission of information in Tase and colleagues since it was a conference abstract [20].

Incidence of Cardiotoxicity

Five out of six studies in our analysis included cardiotoxicity as a primary or secondary outcome. Calvillo-Arguelles et al. specifically defined cardiotoxicity using the two-part CERC definition as described above [19]. Tase et al. and Seician et al. defined cardiotoxicity as new onset heart failure hospitalization [20], [22]. Nabati et al. and Acar et al. defined cardiotoxicity as reduction in LVEF to $<45\%$ and $<50\%$, respectively [23], [24].

Incidence of cardiotoxicity ranged from 5-12% among statin users, and 9-25% among the non-exposed group. Among cohort studies, statins significantly mitigated the risk of cardiotoxicity after anthracycline and/or trastuzumab exposure compared to no statin use [RR=0.46, 95% CI (0.27-0.78), $p=0.004$]. When examining the RCTs, we found a similarly lower relative risk of cardiotoxicity among statin users compared to no statin use, although these results did not achieve statistical significance [RR=0.49, 95% CI (0.17-1.45), $p=0.200$] (Table 4). There was no significant heterogeneity found between studies assessing incidence of cardiotoxicity, among both observational studies ($I^2=0.0\%$; $p=0.800$) and RCTs ($I^2=5.6\%$; $p=0.300$). Due to the small number of studies, publication bias was not assessed.

Change in LV Ejection Fraction

Among statin users, the change in LV ejection fraction ranged from -1.5 to $+1.3\%$. The range of change in LV ejection fraction was -5.2 to -7.9% among non-statin users. Those who used statins were also more likely to maintain LV ejection fraction at the same or higher percentages from baseline after anthracycline and/or trastuzumab exposure, compared to those who did not use statins in the cohort studies [WMD=6.14%, 95% CI (2.75-9.52), $p<.001$] and RCTs [WMD=6.25%, 95% CI (0.82-11.68), $p=.024$] (Table 5). There was significant heterogeneity found between studies assessing mean LVEF change, among both observational studies ($I^2=74.7\%$; $p=0.047$) and RCTs ($I^2=80.9\%$; $p=0.022$). We were not able to examine publication bias because we had less than 10 studies in our analysis.

Discussion

In this study, we found that statin use was associated with a lower risk of cardiotoxicity among patients undergoing anthracycline and/or trastuzumab therapy. This meta-analysis demonstrated that the risk of cardiotoxicity was 50% lower among statin users, although the risk reduction was not significant in the included RCTs. Further, the analyses from cohort and RCTs demonstrated a $\sim 6\%$ difference in the change in LV ejection fraction among statin users compared to those who did not receive statins, suggesting that cancer patients using statins were more likely to preserve their LV ejection fraction during anthracycline and/or trastuzumab therapy, although due to significant heterogeneity, the clinical implications of this are not clear. These findings were consistent across both cohort studies and RCTs.

Cardiotoxicity has many manifestations including subtle changes in myocardial strain or biomarkers, asymptomatic left ventricular systolic dysfunction, or clinical heart failure [25]. Our findings are consistent with prior meta-analyses that have included statins as one of various cardioprotective agents associated with maintaining LV ejection fraction and lowering the risk of cardiotoxicity among patients treated with anthracyclines and/or trastuzumab, compared to placebo or controls [26], [27]. Our study adds to this literature by specifically examining the potential therapeutic benefit of statin use among cancer patients treated with cardiotoxic chemotherapy. While incident cardiotoxicity was not significant in

RCTs, our results suggest that change in LV ejection fraction can be mitigated by statin use even among patients who do not meet criteria for cardiotoxicity as currently defined. This highlights the importance of assessing both incident cardiotoxicity and LV ejection fraction changes.

Increasing awareness of cardiotoxicity among cancer survivors has led to the need for cardioprotective measures. Dexrazoxane is the only drug approved by the Federal Drug Administration to prevent chemotherapy-induced cardiotoxicity; however, concerns related to decreased cancer-specific survival and risk for secondary malignancy have limited its utilization in clinical practice [13], [28], [29]. In contrast, statins have demonstrated potential to reduce the risk of cardiotoxicity and may also be associated with reductions in cancer mortality [30].

Other cardioprotective agents, including beta-blockers (BB), angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs), have demonstrated effectiveness in reducing the risk of cardiotoxicity among cancer patients, as evidenced by various RCTs. ACE inhibitors and BB were associated with increased cardiotoxicity-free survival and fewer interruptions in cancer therapy compared to placebo among HER2 positive breast cancer patients treated with trastuzumab (+/- anthracyclines) [4], [8]. Similarly, among patients treated for hematological cancers, concurrent use of enalapril and carvedilol with anthracyclines in the Prevention of Left Ventricular Dysfunction with Enalapril and Carvedilol in Patients Submitted to Intensive Chemotherapy for the Treatment of Malignant Hemopathies (OVERCOME) trial was associated with a lower incidence of cardiotoxicity and no significant change in LV ejection fraction compared to controls [7]. In contrast, in HER2 negative breast cancer patients treated with anthracyclines, carvedilol did not have an impact on cardiotoxicity incidence or LV ejection fraction [6]. Furthermore, in a trial of early stage breast cancer survivors who received anthracyclines, ARBs (candesartan) were associated with protection against LV dysfunction, whereas the BB (metoprolol) did not have an effect [5]. While there is a signal for reduced cardiotoxicity when using these cardioprotective agents, there is significant heterogeneity in the results making them inconclusive [31].

Patients receiving chemotherapy are especially at risk for hypotension from fluid shifts, infection, etc., and thus anti-hypertensive therapy with ACE inhibitors, ARBs, or BB may not be tolerated. While carvedilol has been shown by many studies to have an impact on reducing cardiotoxicity through its antioxidant and anti-apoptotic properties [32]–[38], it has also been shown to have side effects of symptomatic hypotension and dizziness [6]. Thus, statins may be a better tolerated and may be an appropriate adjunct or alternative to ACE inhibitors, ARBs, or BB for mitigating cardiotoxicity in patients receiving anthracyclines and/or trastuzumab.

Implications from this analysis include the need for large-scale RCTs to understand the impact of statins on preventing cardiotoxicity. Currently, there are several ongoing clinical trials that will hopefully provide clarity about the cardioprotective potential of statin therapy [39]–[41]. Additionally, there is a need to understand if and how statins may impact cancer treatment, although current research suggests that they are safe and may reduce recurrence and improve survival for certain malignancies such as breast cancer [42], [43]. Current clinical guidelines highlight the need for preventing and monitoring cardiotoxicity among cancer survivors, through suggested serial screening during treatment and up to 1-2 years post treatment [44]–[46]. Guidelines currently do not recommend routine concomitant use of cardioprotective drugs (i.e., statins, ACE inhibitors, ARBs, BB) with potentially cardiotoxic cancer therapies. Further data to support the use of statins, or other cardioprotective agents, in primary and/or secondary prevention of cardiotoxicity during treatment could have significant implications for the long-term outcomes of cancer patients.

To our knowledge, this study is the first meta-analysis to exclusively examine the impact of statins on mitigation of cardiotoxicity. We provide a pooled analysis of the available data examining statins as cardioprotective agents in cancer patients treated with anthracyclines and/or trastuzumab. However, this study has several limitations. First, due to the paucity of research examining statins as cardioprotective agents, the sample size of this meta-analysis is small. We attempted to overcome this limitation by including both RCTs and observational studies. However, it is important to note the potential for selection bias among observational studies. Given that statins are a common medication for the general population, cancer patients who were already taking statins may be receiving pre-diagnostic (pre-cancer diagnosis) cardiovascular benefit [47]. As such, there are insufficient data to determine causation between statin use and lower risk of cardiotoxicity, warranting future larger RCTs randomizing by initiation of statin use to understand its clinical benefit. That being said, the observational studies included in our analysis attempted to overcome this source of bias by adequately controlling for factors (such as demographics, comorbid conditions) that are known to affect LVEF through multivariate risk adjustment. However, there is still a possibility that there were unidentifiable sources of bias and confounding that were not included in the models. Cardiotoxicity can develop many years after completion of chemotherapy. The RCTs may have underestimated the cardioprotective benefit of statin therapy due to their limited study duration (6 months). The inclusion of observational studies potentially strengthened our conclusions by allowing longer follow-up. Moreover, because of the small number of studies, we were not able to assess publication bias or conduct a meta-regression or other exploration of heterogeneity. The generalizability of these study findings should be considered in light of these limitations.

In conclusion, statins have the potential to mitigate the cardiotoxic effects of anthracyclines and trastuzumab. Based on these pooled results, cancer survivors on statin therapy during cancer treatment had a lower incidence of cardiotoxicity and were more likely to maintain LV ejection fraction during study follow-up. These data provide support for larger RCTs examining the safety and efficacy of statins as cardioprotective agents in patients receiving anthracycline and/or trastuzumab therapy.

Declarations

Funding: This study was not funded, and no conflicts of interests to be disclosed. Dr. Nohria receives research support from Amgen and is a consultant for AstraZeneca, Takeda Oncology and Boehringer Ingelheim.

Conflicts of interest/Competing interests: No conflicts of interests

Availability of data and material: Available upon request

Code availability: Available upon request

Author Contributions: All authors discussed the results and contributed to the final manuscript.

Acknowledgements: This study was conducted at Harvard T.H. Chan School of Public Health.

References

- [1] M. W. Bloom *et al.*, "Cancer Therapy-Related Cardiac Dysfunction and Heart Failure Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging," *Circ. Heart Fail.*, vol. 9, no. 1, p. e002661, Jan. 2016, doi: 10.1161/CIRCHEARTFAILURE.115.002661.
- [2] Z. Jawa *et al.*, "Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis," *Medicine (Baltimore)*, vol. 95, no. 44, p. e5195, Nov. 2016, doi: 10.1097/MD.0000000000005195.
- [3] B. E. Levis, P. F. Binkley, and C. L. Shapiro, "Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?," *Lancet Oncol.*, vol. 18, no. 8, pp. e445–e456, 2017, doi: 10.1016/S1470-2045(17)30535-1.
- [4] E. Pituskin *et al.*, "Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101–Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity," *J. Clin. Oncol.*, vol. 35, no. 8, pp. 870–877, Mar. 2017, doi: 10.1200/JCO.2016.68.7830.
- [5] G. Gulati *et al.*, "Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol," *Eur. Heart J.*, vol. 37, no. 21, pp. 1671–1680, 01 2016, doi: 10.1093/eurheartj/ehw022.
- [6] M. S. Avila *et al.*, "Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial," *J. Am. Coll. Cardiol.*, vol. 71, no. 20, pp. 2281–2290, 22 2018, doi: 10.1016/j.jacc.2018.02.049.
- [7] X. Bosch *et al.*, "Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies: The OVERCOME Trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)," *J. Am. Coll. Cardiol.*, vol. 61, no. 23, pp. 2355–2362, Jun. 2013, doi: 10.1016/j.jacc.2013.02.072.
- [8] M. Guglin *et al.*, "Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer," *J. Am. Coll. Cardiol.*, vol. 73, no. 22, pp. 2859–2868, Jun. 2019, doi: 10.1016/j.jacc.2019.03.495.
- [9] Narezkina Anna and Nasim Khoban, "Anthracycline Cardiotoxicity," *Circ. Heart Fail.*, vol. 12, no. 3, p. e005910, Mar. 2019, doi: 10.1161/CIRCHEARTFAILURE.119.005910.
- [10] A. Albin, G. Pennesi, F. Donatelli, R. Cammarota, S. De Flora, and D. M. Noonan, "Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention," *JNCI J. Natl. Cancer Inst.*, vol. 102, no. 1, pp. 14–25, Jan. 2010, doi: 10.1093/jnci/djp440.
- [11] E. J. A. Bowles *et al.*, "Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study," *JNCI J. Natl. Cancer Inst.*, vol. 104, no. 17, pp. 1293–1305, Sep. 2012, doi: 10.1093/jnci/djs317.
- [12] S. Ramkumar, A. Raghunath, and S. Raghunath, "Statin Therapy: Review of Safety and Potential Side Effects," *Acta Cardiol. Sin.*, vol. 32, no. 6, pp. 631–639, Nov. 2016, doi: 10.6515/acs20160611a.
- [13] C. Henninger and G. Fritz, "Review Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers Official journal of the Cell Death Differentiation Association," *Nat. Publ. Group*, vol. 8, 2017, doi: 10.1038/cddis.2016.418.
- [14] D. Moher, A. Liberati, J. Tetzlaff, and D. G. Altman, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement," *BMJ*, vol. 339, Jul. 2009, doi: 10.1136/bmj.b2535.
- [15] N. Panic, E. Leoncini, G. de Belvis, W. Ricciardi, and S. Boccia, "Evaluation of the Endorsement of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement on the Quality of Published Systematic Review and Meta-Analyses," *PLoS ONE*, vol. 8, no. 12, Dec. 2013, doi: 10.1371/journal.pone.0083138.

- [16] A. Seidman *et al.*, "Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience," *J. Clin. Oncol.*, vol. 20, no. 5, pp. 1215–1221, Mar. 2002, doi: 10.1200/JCO.2002.20.5.1215.
- [17] W. G. Cochran, "The comparison of percentages in matched samples," *Biometrika*, vol. 37, no. 3–4, pp. 256–266, Dec. 1950.
- [18] J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, "Measuring inconsistency in meta-analyses," *BMJ*, vol. 327, no. 7414, pp. 557–560, Sep. 2003, doi: 10.1136/bmj.327.7414.557.
- [19] O. Calvillo-Arguelles *et al.*, "Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy," *Can. J. Cardiol.*, vol. 35, no. 2, pp. 153–159, Feb. 2019, doi: 10.1016/j.cjca.2018.11.028.
- [20] A. G. Tase, A. Tase, O. Tetiu, G. Savoiu, G. Stanculescu, and M. Mihaila, "HMG-CoA-reductase inhibitor co-therapy lowers the risk for incident heart failure in farmorubicin recipients for two cancer locations," *Eur. Heart J.*, vol. 34, no. suppl_1, Aug. 2013, doi: 10.1093/eurheartj/eh307.141.
- [21] R. Chotenimitkhun *et al.*, "Chronic Statin Administration May Attenuate Early Anthracycline-Associated Declines in Left Ventricular Ejection Function," *Clin. Res.*, 2015, doi: 10.1016/j.cjca.2014.11.020.
- [22] S. Seicean, A. Seicean, J. Carlos Plana, G. Thomas Budd, and T. H. Marwick, "Heart Failure Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients With Breast Cancer Receiving Anthracycline Chemotherapy An Observational Clinical Cohort Study," 2012, doi: 10.1016/j.jacc.2012.07.067.
- [23] M. Nabati, G. Janbabai, J. Esmailian, and J. Yazdani, "Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial," *J. Cardiovasc. Pharmacol. Ther.*, vol. 24, no. 3, pp. 233–241, May 2019, doi: 10.1177/1074248418821721.
- [24] Z. Acar *et al.*, "Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy," *JAC*, vol. 58, pp. 988–989, 2011, doi: 10.1016/j.jacc.2011.05.025.
- [25] "Prevention of Cardiomyopathy in Patients With Cancer," *American College of Cardiology*. <http://www.acc.org/latest-in-cardiology/articles/2016/09/29/13/25/prevention-of-cardiomyopathy-in-patients-with-cancer> (accessed Jun. 20, 2020).
- [26] X. Li *et al.*, "Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials," *Pharmacol. Res.*, vol. 151, p. 104577, Jan. 2020, doi: 10.1016/j.phrs.2019.104577.
- [27] K. Kalam and T. H. Marwick, "Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis," *Eur. J. CANCER*, vol. 49, no. 13, pp. 2900–2909, Sep. 2013, doi: 10.1016/j.ejca.2013.04.030.
- [28] R. S. Cvetković and L. J. Scott, "Dexrazoxane," *Drugs*, vol. 65, no. 7, pp. 1005–1024, May 2005, doi: 10.2165/00003495-200565070-00008.
- [29] P. Vejpongsa and E. T. H. Yeh, "Prevention of Anthracycline-Induced Cardiotoxicity: Challenges and Opportunities," *J. Am. Coll. Cardiol.*, vol. 64, no. 9, pp. 938–945, Sep. 2014, doi: 10.1016/j.jacc.2014.06.1167.
- [30] C. R. Cardwell, B. M. Hicks, C. Hughes, and L. J. Murray, "Statin Use After Diagnosis of Breast Cancer and Survival," *Epidemiology*, vol. 26, no. 1, pp. 68–78, 2014, doi: 10.1097/ede.0000000000000189.
- [31] M. Vaduganathan *et al.*, "Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy," *JACC CardioOncology*, vol. 1, no. 1, pp. 54–65, Sep. 2019, doi: 10.1016/j.jaccao.2019.08.006.
- [32] B. Kheiri *et al.*, "Meta-Analysis of Carvedilol for the Prevention of Anthracycline-Induced Cardiotoxicity," *Am. J. Cardiol.*, vol. 122, Sep. 2018, doi: 10.1016/j.amjcard.2018.08.039.
- [33] A. M. Abuosa *et al.*, "Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin," *Indian Heart J.*, vol. 70 Suppl 3, pp. S96–S100, Dec. 2018, doi: 10.1016/j.ihj.2018.06.011.
- [34] A. Elitok *et al.*, "Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up," *Cardiol. J.*, vol. 21, no. 5, pp. 509–515, 2014, doi: 10.5603/CJ.a2013.0150.
- [35] R. Jhorawat *et al.*, "Preventive role of carvedilol in adriamycin-induced cardiomyopathy," *Indian J. Med. Res.*, vol. 144, no. 5, p. 725, May 2016, doi: 10.4103/ijmr.IJMR_1323_14.
- [36] M. Nabati, G. Janbabai, S. Baghyari, K. Esmaili, and J. Yazdani, "Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity," *J. Cardiovasc. Pharmacol.*, vol. 69, no. 5, pp. 279–285, May 2017, doi: 10.1097/FJC.0000000000000470.

- [37] R. Salehi, B. Zamani, A. Esfehiani, S. Ghafari, M. Abasnezhad, and M. Goldust, "Protective effect of carvedilol in cardiomyopathy caused by anthracyclines in patients suffering from breast cancer and lymphoma," *Am. Heart Hosp. J.*, vol. 9, no. 2, pp. 95–98, 2011, doi: 10.15420/ahhj.2011.9.2.95.
- [38] A. Tashakori Beheshti, H. Mostafavi Toroghi, G. Hosseini, A. Zarifian, F. Homaei Shandiz, and A. Fazlinezhad, "Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial," *Cardiology*, vol. 134, no. 1, pp. 47–53, 2016, doi: 10.1159/000442722.
- [39] "STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines) - Full Text View - ClinicalTrials.gov." <https://clinicaltrials.gov/ct2/show/NCT02943590> (accessed Aug. 20, 2020).
- [40] "Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT) - Full Text View - ClinicalTrials.gov." <https://clinicaltrials.gov/ct2/show/NCT01988571> (accessed Jul. 15, 2020).
- [41] "Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study - Full Text View - ClinicalTrials.gov." <https://clinicaltrials.gov/ct2/show/NCT03186404> (accessed Aug. 20, 2020).
- [42] Q.-J. Wu *et al.*, "Statin use and breast cancer survival and risk: a systematic review and meta-analysis," *Oncotarget*, vol. 6, no. 40, pp. 42988–43004, Dec. 2015, doi: 10.18632/oncotarget.5557.
- [43] S. Borgquist, P. Broberg, J. Tojjar, and H. Olsson, "Statin use and breast cancer survival – a Swedish nationwide study," *BMC Cancer*, vol. 19, no. 1, p. 54, Dec. 2019, doi: 10.1186/s12885-018-5263-z.
- [44] L. S. Mehta *et al.*, "Cardiovascular disease and breast cancer: where these entities intersect: A scientific statement from the American Heart Association," *Circulation*, vol. 137, pp. 30–66, 2018, doi: 10.1161/CIR.0000000000000556.
- [45] G. Curigliano *et al.*, "Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations," *Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.*, vol. 31, no. 2, pp. 171–190, Feb. 2020, doi: 10.1016/j.annonc.2019.10.023.
- [46] National Comprehensive Cancer Network, *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines: Survivorship v2.20)*. 2020.
- [47] S. B. Larsen *et al.*, "Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer," *J. Clin. Oncol.*, vol. 35, no. 29, pp. 3290–3297, Oct. 2017, doi: 10.1200/JCO.2016.71.8981.

Tables

Table 1. Study characteristics

Order	Study design	Statin group	No Statin group	Study length	Mean Age (years)	Male, n (%)	Statin dose, range (prevalence %)	Cancer	Cancer therapy	Matching criteria	Country
10) (19)	Obs	43	86	11 months (IQR 9, 18)	62.0 ± 9.0	0 (0)	Atorvastatin: 20mg* 10-40 (55.8%) Rosuvastatin: 10mg* 5-20 (25.6%) Simvastatin: 20mg* 10-40 (11.6%) Pravastatin: 20mg* 10-20 (7.0%)	Breast	Trastuzumab	Matched on age and anthracycline exposure status (1:2)	Canada
11) (5)	Obs	14	37	6 months	48.0 ± 2.0	18 (54.5)	Atorvastatin (35.7%) Simvastatin (64.3%) 40±5 mg, 5-80	Breast Leukemia Lymphoma	Anthracycline	-	United States
12) (3)	Obs	144	288	2.55 years ± 1.68	53.5 ± 11.2	51 (11.8)	Rosuvastatin (53.5%) Atorvastatin (36.1%) Other statin (10.4%)	Breast Gastric	Anthracycline	Matched on propensity score (1:2)	Romania
13) (2)	Obs	67	134	2.6 years ± 1.7	51.5 ± 10.8	0 (0)	NA	Breast	Anthracycline	Matched on propensity score (1:2)	United States
14) (9)	RCT	38	39	6 months	49.2 ± 11.2	0 (0)	Rosuvastatin 20mg	Breast	Anthracycline Trastuzumab	Randomized to statin or placebo on 1:1 ratio	Iran
15) (1)	RCT	20	20	6 months	53.0 ± 15.0	17 (42.5)	Atorvastatin 40mg	Non-Hodgkin's lymphoma Multiple myeloma Leukemia	Anthracycline	Randomized to statin or no statin on 1:1 ratio	Turkey

Abbreviations: Obs=observational, RCT=randomized control trial, NA=not available

*median dose

Table 2. Cardiotoxicity definition and values, by study.

Order	Cardiac Imaging	Statin group				Control group			
		Mean Baseline LVEF (%)	Mean Final LVEF (%)	Mean Change in LVEF (%)	Cardiotoxicity Incidence	Mean Baseline LVEF (%)	Mean Final LVEF (%)	Mean Change in LVEF (%)	Cardiotoxicity Incidence
10) (19)	MUGA	66.0 ± 7.0	64.6 (IQR 62.2, 67.1)	0 (IQR -5, +3)	5/43, 11.6%	66.7 ± 5.4	61.2 (IQR 59.6, 62.8)	-6 (IQR -10, -1)	21/86, 24.4%
11) (5)	Echocardiogram	55.05 ± 4.84	53.54 ± 6.68	-1.5 ± 6.6	4/38, 10.5%	55.10 ± 5.09	49.95 ± 6.57	-5.2 ± 5.7	6/39, 15.4%
12) (3)	Echocardiogram	61.3 ± 7.9	62.6 ± 9.3	+1.3 ± 3.8	1/20, 5%	62.9 ± 7.0	55.0 ± 9.5	-7.9 ± 8.0	5/20, 25%
13) (2)	Cardiovascular MRI	56.6 ± 1.4	54.1 ± 1.3	+1.1 ± 2.6	-	57.5 ± 1.4	52.4 ± 1.2	-6.5 ± 1.5	-
14) (9)	-	-	-	-	7/144, 4.9%	-	-	-	26/288, 9%
15) (1)	-	-	-	-	4/67, 6%	-	-	-	23/134, 17.2%

Note. Abbreviations: IQR=interquartile range, MUGA=multigated acquisition scan, MRI=magnetic resonance imaging, LVEF=left ventricular ejection fraction

Table 3. Methodological quality of included cohort studies based on Newcastle-Ottawa Scale.

Study	Selection	Comparability	Outcome	Total score
Calvillo-Arguelles (2019)	★ ★	★ ★	★ ★ ★	7
Chotenimitkhun (2015)	★ ★	★ ★	★ ★ ★	7
Tase (2013)		★	★ ★	3
Seicean (2012)	★ ★ ★	★ ★	★ ★ ★	8

Table 4. Pooled relative risk for incidence of cardiotoxicity using random effects model.

Study		RR [95% CI]	% Weight
Observational			
Calvillo-Arguelles et al.		0.476 [0.193 - 1.176]	33.01
Tase et al.		0.538 [0.238 - 1.211]	41.09
Seicean et al.		0.348 [0.125 - 0.965]	25.90
Pooled RR		0.462 [0.275 - 0.776]	100.00
Heterogeneity: $\chi^2=0.44$ (d.f.=2), $p=0.802$, $I^2=0.0\%$ Test of RR=1: $z=2.92$, $p=0.004$			
RCT			
Nabati et al.		0.684 [0.209 - 2.235]	73.69
Acar et al.		0.200 [0.026 - 1.562]	26.31
Pooled RR		0.495 [0.169 - 1.451]	100.00
Heterogeneity: $\chi^2=1.06$ (d.f.=1), $p=0.303$, $I^2=5.6\%$ Test of RR=1: $z=1.28$, $p=0.200$			

Table 5. Estimated weighted mean difference for change in LV ejection fraction using random-effects model with inverse variance weights.

Study		WMD [95% CI]	% Weight
Observational			
Calvillo Arguelles et al.		4.100 [0.969 - 7.231]	41.80
Chotenimitkhun et al.		7.600 [6.155 - 9.045]	58.20
Pooled WMD Heterogeneity: $\chi^2=3.96$ (d.f.=1), $p=0.047$, $I^2=74.7\%$ Test of WMD=0: $z=3.55$, $p<0.001$		6.137 [2.753 - 9.520]	100.00
RCT			
Nabati et al.		3.650 [0.906 - 6.394]	53.19
Acar et al.		9.200 [5.318 - 13.082]	46.81
Pooled WMD Heterogeneity: $\chi^2=5.24$ (d.f.=1), $p=0.022$, $I^2=80.9\%$ Test of WMD=0: $z=2.26$, $p=0.024$		6.248 [0.820 - 11.676]	100.00

Figures




Figure 1

Flow diagram of screened, excluded, and analyzed publications.

	Sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete data	Selective reporting
Acar (2011)	+	+	-	+	+	+
Nabati (2019)	+	+	+	+	+	+

Figure 2

Methodological quality of randomized controlled trials: review authors' opinion on each item of bias risk based on version 2 of the Cochrane risk-of-bias tool for randomized trials (RoB 2). Review authors' opinion on each item of bias risk based on Cochrane handbook. "+", "x," or "-" reflected low risk of bias, high risk of bias, and some concerns, respectively.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplement.pdf](#)